Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
C4 Therapeutics, Inc. (CCCC)
USD3.77
-0.04 (-1.02%)
US NASDAQ Healthcare Biotechnology
Address
490 Arsenal Way 2472
Watertown, MA, US
Watertown, MA, US
CEO
Andrew J. Hirsch
Website
c4therapeutics.com
IPO
2020-10-02
CIK 1662579 ISIN US12529R1077
Description
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
- Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.77
-0.04 (-1.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
2.93
Float Shares
70.28M
Free Float %
84.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +8.93% | +24.80% | +73.22% | +27.82% | +65.97% | +100.63% | -2.76% | -90.95% | -87.56% | -87.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
3.77
Low
7.00
+85.6%
Consensus
7.00
+85.6%
Median
7.00
+85.6%
High
7.00
+85.6%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
7.00
+85.6%
|
| Last Year | 6 |
7.67
+103.4%
|
| All Time | 11 |
10.18
+170.0%
|
Quality scores
Altman Z-Score
-1.80
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+1.0% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+16.5% Q1'26: +45.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-369.8%
-
EBIT margin Biotechnology: +0.0%-291.7%
-
ROIC Biotechnology: -16.1%-154.2% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+19.5% Q1'26: +78.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.58× Q1'26: -0.53× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
33.20M
est: 32.92M (+0.8%)
|
45.79M
est: 33.08M (+38.4%)
|
31.10M
est: 39.80M (-21.9%)
|
20.76M
est: 29.38M (-29.3%)
|
35.58M
est: 35.79M (-0.6%)
|
35.95M
est: 30.36M (+18.4%)
|
21.62M
21.62M – 21.62M
-28.8% YoY
|
19.12M
19.12M – 19.12M
-11.6% YoY
|
17.28M
17.28M – 17.28M
-9.6% YoY
|
600.94M
600.94M – 600.94M
+3,377.0% YoY
|
1.97B
1.97B – 1.97B
+227.5% YoY
|
| EBITDA |
-58.83M
est: -32.92M (-78.7%)
|
-80.26M
est: -96.24M (+16.6%)
|
-124.28M
est: -113.31M (-9.7%)
|
-122.10M
est: -29.38M (-315.6%)
|
-103.37M
est: -35.79M (-188.8%)
|
-102.91M
est: -30.36M (-239.0%)
|
-21.62M
-21.62M – -21.62M
+28.8% YoY
|
-19.12M
-19.12M – -19.12M
+11.6% YoY
|
-17.28M
-17.28M – -17.28M
+9.6% YoY
|
-600.94M
-600.94M – -600.94M
-3,377.0% YoY
|
-1.97B
-1.97B – -1.97B
-227.5% YoY
|
| EBIT |
-60.45M
est: -32.92M (-83.6%)
|
-81.75M
est: -98.51M (+17.0%)
|
-125.96M
est: -116.26M (-8.3%)
|
-129.84M
est: -29.38M (-342.0%)
|
-105.19M
est: -35.79M (-193.9%)
|
-104.87M
est: -30.36M (-245.5%)
|
-21.62M
-21.62M – -21.62M
+28.8% YoY
|
-19.12M
-19.12M – -19.12M
+11.6% YoY
|
-17.28M
-17.28M – -17.28M
+9.6% YoY
|
-600.94M
-600.94M – -600.94M
-3,377.0% YoY
|
-1.97B
-1.97B – -1.97B
-227.5% YoY
|
| Net Income |
-66.33M
est: -550.98M (+88.0%)
|
-83.89M
est: -100.64M (+16.6%)
|
-128.18M
est: -117.73M (-8.9%)
|
-132.49M
est: -150.46M (+11.9%)
|
-105.32M
est: -123.96M (+15.0%)
|
-104.99M
est: -116.19M (+9.6%)
|
-89.75M
-101.69M – -77.82M
+22.8% YoY
|
-82.63M
-91.07M – -74.20M
+7.9% YoY
|
-125.33M
-184.89M – -65.76M
-51.7% YoY
|
18.38M
18.38M – 18.38M
+114.7% YoY
|
319.83M
319.83M – 319.83M
+1,640.6% YoY
|
| SGA |
15.20M
est: 38.00M (-60.0%)
|
33.25M
est: 38.19M (-12.9%)
|
42.79M
est: 45.94M (-6.9%)
|
42.08M
est: 37.14M (+13.3%)
|
42.12M
est: 45.24M (-6.9%)
|
36.20M
est: 38.37M (-5.7%)
|
27.33M
27.33M – 27.33M
-28.8% YoY
|
24.17M
24.17M – 24.17M
-11.6% YoY
|
21.85M
21.85M – 21.85M
-9.6% YoY
|
759.65M
759.65M – 759.65M
+3,377.0% YoY
|
2.49B
2.49B – 2.49B
+227.5% YoY
|
| EPS |
-1.54
est: -7.94 (+80.6%)
|
-1.82
est: -2.05 (+11.2%)
|
-2.62
est: -2.59 (-1.1%)
|
-2.67
est: -1.82 (-47.1%)
|
-1.52
est: -1.49 (-2.0%)
|
-1.27
est: -1.41 (+9.7%)
|
-1.09
-1.23 – -0.94
+22.6% YoY
|
-1.00
-1.10 – -0.90
+8.0% YoY
|
-1.31
-2.23 – -0.79
-30.4% YoY
|
0.22
0.22 – 0.22
+117.0% YoY
|
3.86
3.86 – 3.86
+1,640.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-98.77M
OE per share TTM
-1.35
Owner's Yield
-37.59%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
146.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
27
Total invested
43.06M
Insider transactions (90d)
0
Beneficial owners (>5%)
40
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STATE STREET CORPORATION | 7.15M | 10.43% | — | 7.15M | — | 7.15M | HC | BOSTON, MASSACHUSETTS | 2024-04-10 | ↗ |
| 2 | SSGA FUNDS MANAGEMENT, INC. | 6.98M | 10.18% | — | 6.98M | — | 6.98M | IA | BOSTON, MASSACHUSETTS | 2024-04-10 | ↗ |
| 3 | ArrowMark Colorado Holdings, LLC | 5.80M | 11.85% | 5.80M | — | 5.80M | — | IA | Delaware, United States | 2023-02-14 | ↗ |
| 4 | Betta Investment (Hong Kong) Limited | 5.57M | 8.10% | 5.57M | — | 5.57M | — | OO | Hong Kong | 2024-01-12 | ↗ |
| 5 | Betta Pharmaceuticals Co., Ltd. | 5.57M | 8.10% | 5.57M | — | 5.57M | — | OO | Hong Kong | 2024-01-12 | ↗ |
| 6 | (1) BlackRock, Inc. | 4.89M | 7.10% | 4.79M | — | 4.79M | — | HC | Delaware | 2024-11-08 | ↗ |
| 7 | Peter Kolchinsky | 4.88M | 9.90% | — | 4.88M | — | 4.88M | HC, IN | Delaware | 2023-12-26 | ↗ |
| 8 | RA Capital Healthcare Fund, L.P. | 4.88M | 9.90% | — | 4.88M | — | 4.88M | PN | Delaware | 2023-12-26 | ↗ |
| 9 | RA Capital Management, L.P. | 4.88M | 9.90% | — | 4.88M | — | 4.88M | IA, PN | Delaware | 2023-12-26 | ↗ |
| 10 | Rajeev Shah | 4.88M | 9.90% | — | 4.88M | — | 4.88M | HC, IN | Delaware | 2023-12-26 | ↗ |
| 11 | Alain Cohen | 4.21M | 9.80% | 1.72M | 2.48M | 1.72M | 11.00 | IN | — | 2020-10-16 | ↗ |
| 12 | 52-0556948 | 4.08M | 8.40% | 820.4K | — | 4.08M | — | IA | Maryland | 2022-02-14 | ↗ |
| 13 | Capital LP | 3.80M | 7.70% | — | 3.80M | — | 3.80M | IA | Cayman Islands | 2023-12-22 | ↗ |
| 14 | Capital Master LP | 3.80M | 7.70% | — | 3.80M | — | 3.80M | OO | Cayman Islands | 2023-12-22 | ↗ |
| 15 | Lynx1 Capital Management LP | 3.12M | 6.30% | — | 3.12M | — | — | PN | United States of America | 2023-11-13 | ↗ |
| 16 | Weston Nichols | 3.12M | 6.30% | — | 3.12M | — | — | IN | United States of America | 2023-11-13 | ↗ |
| 17 | OrbiMed Capital LLC | 2.93M | 4.20% | 2.93M | — | 2.93M | — | IA | Delaware | 2024-11-14 | ↗ |
| 18 | Steven A. Cohen | 2.68M | 5.40% | — | 2.68M | — | — | IN | Delaware | 2024-01-04 | ↗ |
| 19 | Guy Levy | 2.56M | 5.20% | — | 2.56M | — | 2.56M | IN | United States | 2024-02-05 | ↗ |
| 20 | Soleus Capital Group, LLC | 2.56M | 5.20% | — | 2.56M | — | 2.56M | OO | United States | 2024-02-05 | ↗ |
| 21 | Soleus Capital Master Fund, L.P. | 2.56M | 5.20% | — | 2.56M | — | 2.56M | FI | United States | 2024-02-05 | ↗ |
| 22 | Soleus Capital, LLC | 2.56M | 5.20% | — | 2.56M | — | 2.56M | OO | United States | 2024-02-05 | ↗ |
| 23 | RTW Investments, LP | 2.49M | 5.10% | — | 2.49M | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 24 | Roderick Wong | 2.49M | 5.10% | — | 2.49M | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 25 | Bihua Chen | 2.49M | 5.79% | — | 2.49M | — | 2.49M | IN | United States | 2021-02-16 | ↗ |
| 26 | Cormorant Asset Management, LP | 2.49M | 5.79% | — | 2.49M | — | 2.49M | PN | Delaware | 2021-02-16 | ↗ |
| 27 | Israel A. Englander | 2.37M | 4.80% | — | 2.37M | — | 2.37M | IN | Delaware | 2023-07-25 | ↗ |
| 28 | Millennium Group Management LLC | 2.37M | 4.80% | — | 2.37M | — | 2.37M | OO | Delaware | 2023-07-25 | ↗ |
| 29 | Millennium Management LLC | 2.37M | 4.80% | — | 2.37M | — | 2.37M | OO | Delaware | 2023-07-25 | ↗ |
| 30 | Point72 Asset Management, L.P. | 2.31M | 4.70% | — | 2.31M | — | — | PN | Delaware | 2024-01-04 | ↗ |
| 31 | Point72 Capital Advisors, Inc. | 2.31M | 4.70% | — | 2.31M | — | — | CO | Delaware | 2024-01-04 | ↗ |
| 32 | Advisors LLC | 2.21M | 4.50% | — | 2.21M | — | 2.21M | IA | Delaware | 2022-02-14 | ↗ |
| 33 | Edelman | 2.21M | 4.50% | — | 2.21M | — | — | IN | Delaware | 2022-02-14 | ↗ |
| 34 | Sciences Master Fund, Ltd. | 2.21M | 4.50% | — | 2.21M | — | — | CO | Delaware | 2022-02-14 | ↗ |
| 35 | Cormorant Private Healthcare Fund I, LP | 1.87M | 4.34% | — | 1.87M | — | 1.87M | PN | Delaware | 2021-02-16 | ↗ |
| 36 | Cormorant Private Healthcare GP, LLC | 1.87M | 4.34% | — | 1.87M | — | 1.87M | OO | Delaware | 2021-02-16 | ↗ |
| 37 | OrbiMed Advisors LLC | 1.45M | 2.10% | — | 1.45M | — | — | IA | Delaware | 2024-11-14 | ↗ |
| 38 | Cormorant Global Healthcare GP, LLC | 522.0K | 1.21% | — | 522.0K | — | 522.0K | OO | Delaware | 2021-02-16 | ↗ |
| 39 | Cormorant Global Healthcare Master Fund, LP | 522.0K | 1.21% | — | 522.0K | — | 522.0K | PN | Cayman Islands | 2021-02-16 | ↗ |
| 40 | Cubist Systematic Strategies, LLC | 364.6K | 0.70% | — | 364.6K | — | — | OO | Delaware | 2024-01-04 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
27
-81 vs prev Q
New positions
5
Closed positions
80
Increased
12
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | POINT72 ASSET MANAGEMENT, L.P. | 9.44M +9.4M (+100.0%) | 18.03M +18.0M (+100.0%) | 13.01% +13.008 pp | 0.02% +0.020 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 2 | MORGAN STANLEY | 8.98M +4.0M (+80.6%) | 17.15M +6.1M (+55.4%) | 12.38% +5.375 pp | 0.00% +0.000 pp | USD3.60 -46.9% | 21 qtrs — |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 8.00M +8.0M (+100.0%) | 15.28M +15.3M (+100.0%) | 11.02% +11.025 pp | 0.16% +0.157 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 4 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 7.17M +6.1M (+545.0%) | 13.70M +11.2M (+454.9%) | 9.88% +8.318 pp | 1.05% +0.885 pp | USD6.75 -71.7% | 21 qtrs — |
| 5 | LYNX1 CAPITAL MANAGEMENT LP | 7.10M +— (+0.0%) | 13.56M -2.2M (-14.0%) | 9.78% -0.215 pp | 2.74% -0.463 pp | USD4.78 -60.0% | 10 qtrs — |
| 6 | VANGUARD GROUP INC | 4.38M +1.2M (+37.2%) | 8.37M +1.3M (+18.1%) | 6.04% +1.541 pp | 0.00% +0.000 pp | USD15.95 -88.0% | 21 qtrs — |
| 7 | WASATCH ADVISORS LP | 4.34M -507.8K (-10.5%) | 8.30M -2.5M (-23.0%) | 5.99% -0.847 pp | 0.05% -0.009 pp | USD8.12 -76.5% | 20 qtrs — |
| 8 | SOLEUS CAPITAL MANAGEMENT, L.P. | 3.80M -3.3M (-46.1%) | 7.27M -8.4M (-53.6%) | 5.24% -4.692 pp | 0.27% -0.520 pp | USD6.34 -69.9% | 21 qtrs — |
| 9 | BANK OF AMERICA CORP /DE/ | 2.39M +334.4K (+16.3%) | 4.56M +2.3K (+0.0%) | 3.29% +0.399 pp | 0.00% +0.000 pp | USD4.74 -59.7% | 21 qtrs — |
| 10 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.99M +96.8K (+5.1%) | 3.81M -403.2K (-9.6%) | 2.75% +0.076 pp | 0.53% -0.039 pp | USD2.20 -13.2% | 8 qtrs — |
| 11 | BLACKROCK, INC. | 1.97M +374.2K (+23.4%) | 3.76M +220.0K (+6.2%) | 2.71% +0.467 pp | 0.00% +0.000 pp | USD4.78 -60.0% | 6 qtrs — |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.78M +1.3M (+244.5%) | 3.39M +2.2M (+196.4%) | 2.45% +1.721 pp | 0.00% +0.000 pp | USD2.04 -6.4% | 20 qtrs — |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 1.60M +665.6K (+71.0%) | 3.06M +980.9K (+47.2%) | 2.21% +0.889 pp | 0.00% +0.002 pp | USD1.65 +15.8% | 4 qtrs — |
| 14 | TWO SIGMA INVESTMENTS, LP | 1.51M +674.9K (+80.9%) | 2.88M +1.0M (+55.6%) | 2.08% +0.905 pp | 0.00% +0.001 pp | USD3.88 -50.8% | 19 qtrs — |
| 15 | ORBIMED ADVISORS LLC | 1.40M -3.8M (-73.2%) | 2.68M -8.9M (-76.9%) | 1.94% -5.437 pp | 0.06% -0.219 pp | USD4.04 -52.7% | 7 qtrs — |
| 16 | MILLENNIUM MANAGEMENT LLC | 1.19M -745.3K (-38.5%) | 2.27M -2.0M (-47.1%) | 1.64% -1.086 pp | 0.00% -0.001 pp | USD1.84 +3.8% | 12 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 1.09M +629.1K (+136.8%) | 2.08M +1.1M (+103.7%) | 1.50% +0.853 pp | 0.00% +0.000 pp | USD3.54 -46.0% | 21 qtrs — |
| 18 | TWO SIGMA ADVISERS, LP | 1.07M +305.1K (+40.0%) | 2.04M +346.2K (+20.4%) | 1.47% +0.397 pp | 0.00% +0.001 pp | USD6.04 -68.4% | 16 qtrs — |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 988.9K +263.6K (+36.3%) | 1.89M +278.5K (+17.3%) | 1.36% +0.341 pp | 0.00% +0.000 pp | USD10.12 -81.1% | 21 qtrs — |
| 20 | JANE STREET GROUP, LLC | 874.8K +671.2K (+329.7%) | 1.67M +1.2M (+269.7%) | 1.21% +0.919 pp | 0.00% +0.000 pp | USD1.82 +4.9% | 12 qtrs — |
| 21 | WELLS FARGO & COMPANY/MN | 809.3K +790.6K (+4,236.9%) | 1.55M +1.5M (+3,631.3%) | 1.12% +1.089 pp | 0.00% +0.000 pp | USD1.92 -0.5% | 21 qtrs — |
| 22 | ACADIAN ASSET MANAGEMENT LLC | 657.2K +529.1K (+413.0%) | 1.25M +969.0K (+343.6%) | 0.91% +0.725 pp | 0.00% +0.002 pp | USD1.82 +4.9% | 4 qtrs — |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 449.4K +98.8K (+28.2%) | 858.4K +80.1K (+10.3%) | 0.62% +0.126 pp | 0.00% +0.000 pp | USD13.50 -85.9% | 21 qtrs — |
| 24 | CITADEL ADVISORS LLC | 447.8K -33.6K (-7.0%) | 855.3K -213.5K (-20.0%) | 0.62% -0.061 pp | 0.00% +0.000 pp | USD2.22 -14.0% | 2 qtrs — |
| 25 | WALLEYE CAPITAL LLC | 443.3K +443.3K (+100.0%) | 846.8K +846.8K (+100.0%) | 0.61% +0.611 pp | 0.00% +0.003 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 26 | 683 CAPITAL MANAGEMENT, LLC | 400.0K +400.0K (+100.0%) | 764.0K +764.0K (+100.0%) | 0.55% +0.551 pp | 0.03% +0.033 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 27 | STATE STREET CORP | 342.8K +55.4K (+19.3%) | 654.7K +16.7K (+2.6%) | 0.47% +0.068 pp | 0.00% +0.000 pp | USD7.23 -73.6% | 21 qtrs — |
| 28 | DIMENSIONAL FUND ADVISORS LP | 296.5K -52.8K (-15.1%) | 566.5K -209.0K (-27.0%) | 0.41% -0.083 pp | 0.00% +0.000 pp | USD7.73 -75.3% | 14 qtrs — |
| 29 | QUBE RESEARCH & TECHNOLOGIES LTD | 290.2K +174.3K (+150.3%) | 554.3K +296.9K (+115.3%) | 0.40% +0.237 pp | 0.00% +0.000 pp | USD2.03 -5.9% | 2 qtrs — |
| 30 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 272.1K +— (+0.0%) | 519.6K -84.3K (-14.0%) | 0.37% -0.008 pp | 0.01% -0.002 pp | USD1.85 +3.2% | 3 qtrs — |
| 31 | INVESCO LTD. | 268.4K +76.5K (+39.9%) | 512.5K +86.7K (+20.4%) | 0.37% +0.100 pp | 0.00% +0.000 pp | USD2.74 -30.3% | 21 qtrs — |
| 32 | MARSHALL WACE, LLP | 265.0K +158.8K (+149.4%) | 506.2K +270.3K (+114.6%) | 0.37% +0.216 pp | 0.00% +0.000 pp | USD2.03 -5.9% | 2 qtrs — |
| 33 | FMR LLC | 254.4K +43.1K (+20.4%) | 485.9K +16.7K (+3.6%) | 0.35% +0.053 pp | 0.00% +0.000 pp | USD4.51 -57.6% | 21 qtrs — |
| 34 | LPL FINANCIAL LLC | 243.3K +42.4K (+21.1%) | 464.7K +18.6K (+4.2%) | 0.34% +0.052 pp | 0.00% +0.000 pp | USD2.70 -29.3% | 7 qtrs — |
| 35 | HENNION & WALSH ASSET MANAGEMENT, INC. | 237.1K +32.1K (+15.7%) | 452.9K -2.2K (-0.5%) | 0.33% +0.038 pp | 0.02% -0.001 pp | USD4.45 -57.1% | 7 qtrs — |
| 36 | BARCLAYS PLC | 219.2K -24.3K (-10.0%) | 418.7K -969.0K (-69.8%) | 0.30% -0.041 pp | 0.00% 0.000 pp | USD2.86 -33.2% | 16 qtrs — |
| 37 | ARROWMARK COLORADO HOLDINGS LLC | 204.5K +— (+0.0%) | 390.6K -63.4K (-14.0%) | 0.28% -0.006 pp | 0.01% +0.000 pp | USD3.61 -47.1% | 21 qtrs — |
| 38 | NORTHERN TRUST CORP | 166.2K +27.9K (+20.2%) | 317.5K +10.4K (+3.4%) | 0.23% +0.034 pp | 0.00% +0.000 pp | USD9.15 -79.1% | 21 qtrs — |
| 39 | MAN GROUP PLC | 156.1K +65.8K (+72.9%) | 298.1K +97.7K (+48.8%) | 0.22% +0.088 pp | 0.00% +0.000 pp | USD1.78 +7.3% | 4 qtrs — |
| 40 | SQUAREPOINT OPS LLC | 136.1K +126.0K (+1,247.2%) | 259.9K +237.4K (+1,059.1%) | 0.19% +0.173 pp | 0.00% +0.000 pp | USD1.87 +2.1% | 3 qtrs — |
| 41 | QUADRATURE CAPITAL LTD | 133.1K +133.1K (+100.0%) | 254.2K +254.2K (+100.0%) | 0.18% +0.183 pp | 0.00% +0.003 pp | USD1.91 +0.0% | 4 qtrs — |
| 42 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 131.1K +51.2K (+64.1%) | 250.4K +73.0K (+41.2%) | 0.18% +0.068 pp | 0.01% +0.002 pp | USD1.72 +11.0% | 4 qtrs — |
| 43 | MARINER, LLC | 128.1K -187.0 (-0.1%) | 244.8K -39.9K (-14.0%) | 0.18% -0.004 pp | 0.00% 0.000 pp | USD16.22 -88.2% | 16 qtrs — |
| 44 | OMERS ADMINISTRATION CORP | 117.7K +117.7K (+100.0%) | 224.8K +224.8K (+100.0%) | 0.16% +0.162 pp | 0.00% +0.002 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 45 | HUDSON BAY CAPITAL MANAGEMENT LP | 111.6K +111.6K (+100.0%) | 213.1K +213.1K (+100.0%) | 0.15% +0.154 pp | 0.00% +0.001 pp | USD1.91 +0.0% | 3 qtrs — |
| 46 | ATOM INVESTORS LP | 105.0K +105.0K (+100.0%) | 200.5K +200.5K (+100.0%) | 0.14% +0.145 pp | 0.02% +0.016 pp | USD1.91 +0.0% | 8 qtrs — |
| 47 | XTX TOPCO LTD | 104.5K -45.5K (-30.3%) | 199.5K -133.4K (-40.1%) | 0.14% -0.067 pp | 0.01% -0.012 pp | USD1.70 +12.4% | 6 qtrs — |
| 48 | GRAHAM CAPITAL MANAGEMENT, L.P. | 102.2K +61.6K (+151.5%) | 195.2K +105.0K (+116.4%) | 0.14% +0.084 pp | 0.00% +0.003 pp | USD2.03 -5.9% | 2 qtrs — |
| 49 | VIENNA POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. VIENNA INSURANCE GROUP | 85.0K +— (+0.0%) | 162.4K -26.4K (-14.0%) | 0.12% -0.003 pp | 0.08% -0.032 pp | USD28.46 -93.3% | 17 qtrs — |
| 50 | AMERICAN CENTURY COMPANIES INC | 68.2K +44.0K (+181.4%) | 130.3K +76.5K (+142.1%) | 0.09% +0.060 pp | 0.00% +0.000 pp | USD2.02 -5.4% | 13 qtrs — |
| 51 | SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 67.6K +— (+0.0%) | 129.1K -21.0K (-14.0%) | 0.09% -0.002 pp | 0.00% -0.002 pp | USD2.63 -27.4% | 5 qtrs — |
| 52 | CRESTWOOD ADVISORS GROUP LLC | 66.5K +— (+0.0%) | 127.1K -20.6K (-14.0%) | 0.09% -0.002 pp | 0.00% 0.000 pp | USD1.88 +1.6% | 3 qtrs — |
| 53 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 62.2K +62.2K (+100.0%) | 118.7K +118.7K (+100.0%) | 0.09% +0.086 pp | 0.00% +0.001 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 54 | INTREPID FAMILY OFFICE LLC | 55.0K -15.0K (-21.4%) | 105.1K -50.4K (-32.4%) | 0.08% -0.023 pp | 0.09% -0.040 pp | USD3.01 -36.5% | 5 qtrs — |
| 55 | D. E. SHAW & CO., INC. | 52.9K +41.0K (+345.7%) | 101.0K +74.7K (+283.5%) | 0.07% +0.056 pp | 0.00% +0.000 pp | USD2.67 -28.5% | 21 qtrs — |
| 56 | UBS GROUP AG | 52.8K -8.9K (-14.4%) | 100.8K -36.1K (-26.4%) | 0.07% -0.014 pp | 0.00% +0.000 pp | USD6.73 -71.6% | 21 qtrs — |
| 57 | CITIGROUP INC | 49.8K +46.6K (+1,427.0%) | 95.2K +87.9K (+1,213.7%) | 0.07% +0.064 pp | 0.00% +0.000 pp | USD2.19 -12.8% | 21 qtrs — |
| 58 | CATALYST FUNDS MANAGEMENT PTY LTD | 42.5K +— (+0.0%) | 81.2K -13.2K (-14.0%) | 0.06% -0.001 pp | 0.02% +0.005 pp | USD1.69 +13.0% | 3 qtrs — |
| 59 | GROUP ONE TRADING, L.P. | 39.0K +26.6K (+213.7%) | 74.5K +46.9K (+169.9%) | 0.05% +0.036 pp | 0.00% +0.000 pp | USD2.01 -5.0% | 7 qtrs — |
| 60 | COLONY GROUP, LLC | 38.2K +38.2K (+100.0%) | 72.9K +72.9K (+100.0%) | 0.05% +0.053 pp | 0.00% +0.000 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 61 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 37.7K +37.7K (+100.0%) | 72.0K +72.0K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.000 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 62 | JEFFERIES FINANCIAL GROUP INC. | 35.3K -2.9K (-7.5%) | 67.5K -17.3K (-20.4%) | 0.05% -0.005 pp | 0.00% 0.000 pp | USD2.22 -14.0% | 2 qtrs — |
| 63 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 33.7K +33.7K (+100.0%) | 64.3K +64.3K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.002 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 64 | CALLAN FAMILY OFFICE, LLC | 31.7K +31.7K (+100.0%) | 60.6K +60.6K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.001 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 65 | SIMPLEX TRADING, LLC | 30.7K +22.8K (+291.2%) | 58.6K +41.6K (+244.4%) | 0.04% +0.031 pp | 0.00% +0.000 pp | USD1.99 -4.0% | 2 qtrs — |
| 66 | CANADA PENSION PLAN INVESTMENT BOARD | 29.5K +29.5K (+100.0%) | 56.3K +56.3K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.000 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 67 | FARALLON CAPITAL MANAGEMENT LLC | 28.0K +— (+0.0%) | 53.5K -8.7K (-14.0%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD8.10 -76.4% | 8 qtrs — |
| 68 | TOWER RESEARCH CAPITAL LLC (TRC) | 26.0K +17.6K (+208.8%) | 49.6K +30.9K (+165.7%) | 0.04% +0.024 pp | 0.00% +0.001 pp | USD1.95 -2.1% | 21 qtrs — |
| 69 | CRESSET ASSET MANAGEMENT, LLC | 25.0K +— (+0.0%) | 47.8K -7.8K (-14.0%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD4.73 -59.6% | 17 qtrs — |
| 70 | ENGINEERS GATE MANAGER LP | 24.4K +8.1K (+49.9%) | 46.6K +10.5K (+29.0%) | 0.03% +0.011 pp | 0.00% +0.000 pp | USD1.78 +7.3% | 8 qtrs — |
| 71 | CI PRIVATE WEALTH, LLC | 21.4K -1.3K (-5.8%) | 40.9K -9.5K (-18.9%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD2.02 -5.4% | 13 qtrs — |
| 72 | VIRTU FINANCIAL LLC | 20.7K +20.7K (+100.0%) | 39.0K +39.0K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.002 pp | USD1.91 +0.0% | 3 qtrs — |
| 73 | DELTA INVESTMENT MANAGEMENT, LLC | 20.0K +20.0K (+100.0%) | 38.2K +38.2K (+100.0%) | 0.03% +0.028 pp | 0.01% +0.007 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 74 | EWA, LLC | 16.9K -2.6K (-13.4%) | 32.3K -11.1K (-25.5%) | 0.02% -0.004 pp | 0.01% -0.004 pp | USD1.55 +23.2% | 3 qtrs — |
| 75 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 15.8K +3.3K (+26.6%) | 30.2K +2.5K (+8.9%) | 0.02% +0.004 pp | 0.00% +0.000 pp | USD3.24 -41.0% | 5 qtrs — |
| 76 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 15.2K +650.0 (+4.5%) | 29.1K -3.3K (-10.1%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD1.61 +18.6% | 4 qtrs — |
| 77 | PRUDENTIAL FINANCIAL INC | 15.1K +750.0 (+5.2%) | 28.7K -3.0K (-9.5%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD2.20 -13.2% | 2 qtrs — |
| 78 | HSBC HOLDINGS PLC | 13.6K +— (+0.0%) | 26.2K -3.9K (-12.9%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD4.71 -59.4% | 6 qtrs — |
| 79 | R SQUARED LTD | 13.7K -4.2K (-23.5%) | 26.1K -13.6K (-34.2%) | 0.02% -0.006 pp | 0.01% -0.005 pp | USD1.43 +33.6% | 5 qtrs — |
| 80 | JAIN GLOBAL LLC | 12.8K +12.8K (+100.0%) | 24.4K +24.4K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD1.91 +0.0% | 4 qtrs — |
| 81 | PRICE T ROWE ASSOCIATES INC /MD/ | 12.4K +— (+0.0%) | 24.0K -4.0K (-14.3%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD9.76 -80.4% | 21 qtrs — |
| 82 | NINE MASTS CAPITAL LTD | 11.5K +11.5K (+100.0%) | 21.9K +21.9K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.004 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 83 | ETHIC INC. | 10.3K -230.0 (-2.2%) | 19.6K -3.7K (-15.8%) | 0.01% -0.001 pp | 0.00% 0.000 pp | USD1.43 +33.6% | 3 qtrs — |
| 84 | SIMPLICITY WEALTH,LLC | 10.2K -11.0 (-0.1%) | 19.5K -3.2K (-14.1%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD2.22 -14.0% | 2 qtrs — |
| 85 | ABEL HALL, LLC | 10.1K +— (+0.0%) | 19.4K -3.1K (-14.0%) | 0.01% 0.000 pp | 0.00% -0.005 pp | USD1.43 +33.6% | 3 qtrs — |
| 86 | BRONTE CAPITAL MANAGEMENT PTY LTD. | 10.0K +10.0K (+100.0%) | 19.2K +19.2K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.002 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 87 | BLACKSTON FINANCIAL ADVISORY GROUP, LLC | 10.0K +10.0K (+100.0%) | 19.1K +19.1K (+100.0%) | 0.01% +0.014 pp | 0.01% +0.012 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 88 | JPMORGAN CHASE & CO | 5.9K +1.5K (+34.2%) | 11.4K +1.5K (+15.5%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD3.84 -50.3% | 21 qtrs — |
| 89 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 4.7K +2.0K (+71.2%) | 9.0K +2.9K (+47.3%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD2.72 -29.8% | 5 qtrs — |
| 90 | ADVISOR GROUP HOLDINGS, INC. | 4.5K +14.0 (+0.3%) | 8.7K -2.6K (-23.1%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.96 -2.6% | 3 qtrs — |
| 91 | NBC SECURITIES, INC. | 4.0K +4.0K (+100.0%) | 7.6K +7.6K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.001 pp | USD1.91 +0.0% | 1 qtrs NEW |
| 92 | RHUMBLINE ADVISERS | 2.7K +— (+0.0%) | 5.2K -842.0 (-14.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD5.20 -63.3% | 21 qtrs — |
| 93 | BNP PARIBAS ARBITRAGE, SNC | 2.2K -78.6K (-97.3%) | 4.1K -175.3K (-97.7%) | 0.00% -0.111 pp | 0.00% 0.000 pp | USD1.51 +26.5% | 5 qtrs — |
| 94 | GF FUND MANAGEMENT CO. LTD. | 1.9K +440.0 (+30.1%) | 3.6K +387.0 (+11.9%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD2.97 -35.7% | 5 qtrs — |
| 95 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 1.2K -17.9K (-93.6%) | 2.3K -40.2K (-94.5%) | 0.00% -0.025 pp | 0.00% -0.029 pp | USD2.22 -14.0% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 55 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.46% | 101.9K | 0.20% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.23% | 490.2K | 0.50% |
| 3 | iShares Micro-Cap ETF IWC | 0.09% | 1.38M | 0.60% |
| 4 | Fidelity Enhanced Small Cap ETF FESM | 0.06% | 3.18M | 0.28% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.03% | 350.1K | 0.35% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 23.4K | 0.35% |
| 7 | iShares Biotechnology ETF IBB | 0.03% | 2.93M | 0.44% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 142.9K | 0.40% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.03% | 23.1K | 0.19% |
| 10 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.03% | 839.4K | 0.34% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
9.6K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+9,629
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 5,370 | 2.70 | 14.5K | 71,512 | D | ↗ |
| 2026-04-01 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 4,259 | 2.70 | 11.5K | 68,230 | D | ↗ |
| 2026-02-15 | Hirsch Andrew | Director / Officer | F-InKind | D | Common Stock | 9,057 | 1.89 | 17.1K | 1,074,934 | D | ↗ |
| 2026-02-14 | Schick Kelly | Officer | F-InKind | D | Common Stock | 7,269 | 1.89 | 13.7K | 299,881 | D | ↗ |
| 2026-02-14 | REYNO LEONARD | Officer | F-InKind | D | Common Stock | 16,579 | 1.89 | 31.3K | 379,803 | D | ↗ |
| 2026-02-14 | Mossler Mark | Officer | M-Exempt | A | Common Stock | 9,420 | 0.00 | — | 75,184 | D | ↗ |
| 2026-02-14 | Mahaney Paige | Officer | F-InKind | D | Common Stock | 2,446 | 1.89 | 4.6K | 336,910 | D | ↗ |
| 2026-02-14 | Hirsch Andrew | Director / Officer | F-InKind | D | Common Stock | 39,154 | 1.89 | 74.0K | 1,083,991 | D | ↗ |
| 2026-02-14 | Boyle Scott N | Officer | F-InKind | D | Common Stock | 7,269 | 1.89 | 13.7K | 298,801 | D | ↗ |
| 2026-02-14 | Adams Kendra | Officer | M-Exempt | A | Common Stock | 30,950 | 0.00 | — | 400,479 | D | ↗ |
| 2026-02-13 | Schick Kelly | Officer | F-InKind | D | Common Stock | 1,735 | 1.89 | 3.3K | 307,150 | D | ↗ |
| 2026-02-13 | REYNO LEONARD | Officer | A-Award | A | Common Stock | 240,000 | 0.00 | — | 396,382 | D | ↗ |
| 2026-02-13 | Mossler Mark | Officer | A-Award | A | Common Stock | 56,980 | 0.00 | — | 75,184 | D | ↗ |
| 2026-02-13 | Mahaney Paige | Officer | A-Award | A | Common Stock | 240,000 | 0.00 | — | 339,356 | D | ↗ |
| 2026-02-13 | Hirsch Andrew | Director / Officer | A-Award | A | Common Stock | 700,000 | 0.00 | — | 1,123,145 | D | ↗ |
| 2026-02-13 | Boyle Scott N | Officer | F-InKind | D | Common Stock | 1,735 | 1.89 | 3.3K | 306,070 | D | ↗ |
| 2026-02-13 | Adams Kendra | Officer | F-InKind | D | Common Stock | 1,863 | 1.89 | 3.5K | 400,479 | D | ↗ |
| 2026-01-16 | REYNO LEONARD | Officer | S-Sale | D | Common Stock | 10,000 | 2.22 | 22.2K | 156,382 | D | ↗ |
| 2026-01-02 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 7,513 | 1.93 | 14.5K | 66,142 | D | ↗ |
| 2026-01-02 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 5,958 | 1.93 | 11.5K | 146,532 | D | ↗ |
| 2025-10-28 | Mahaney Paige | Officer | F-InKind | D | Common Stock | 5,644 | 2.58 | 14.6K | 99,356 | D | ↗ |
| 2025-10-01 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 6,740 | 2.15 | 14.5K | 58,629 | D | ↗ |
| 2025-10-01 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 5,349 | 2.15 | 11.5K | 140,574 | D | ↗ |
| 2025-09-18 | Adams Kendra | Officer | M-Exempt | A | Common Stock | 6,250 | 0.00 | — | 165,117 | D | ↗ |
| 2025-07-10 | REYNO LEONARD | Officer | M-Exempt | A | Common Stock | 15,325 | 0.00 | — | 173,764 | D | ↗ |
| 2025-07-01 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 9,609 | 1.51 | 14.5K | 51,889 | D | ↗ |
| 2025-07-01 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 7,616 | 1.51 | 11.5K | 135,225 | D | ↗ |
| 2025-06-18 | Koppikar Utpal | Director | A-Award | A | Stock Option (Right to Buy) | 35,500 | 1.44 | 51.1K | 35,500 | D | ↗ |
| 2025-06-18 | Hughes Owen | Director | A-Award | A | Stock Option (Right to Buy) | 35,500 | 1.44 | 51.1K | 35,500 | D | ↗ |
| 2025-06-18 | Hoerter Steven L. | Director | A-Award | A | Stock Option (Right to Buy) | 35,500 | 1.44 | 51.1K | 35,500 | D | ↗ |
| 2025-06-18 | GROGAN DONNA ROY | Director | A-Award | A | Stock Option (Right to Buy) | 35,500 | 1.44 | 51.1K | 35,500 | D | ↗ |
| 2025-06-18 | Fawell Stephen | Director | A-Award | A | Stock Option (Right to Buy) | 35,500 | 1.44 | 51.1K | 35,500 | D | ↗ |
| 2025-06-18 | Cooper Ronald Harold Wilfred | Director | A-Award | A | Stock Option (Right to Buy) | 35,500 | 1.44 | 51.1K | 35,500 | D | ↗ |
| 2025-06-18 | Bessen Laura | Director | A-Award | A | Stock Option (Right to Buy) | 35,500 | 1.44 | 51.1K | 35,500 | D | ↗ |
| 2025-06-18 | Anderson Kenneth Carl | Director | A-Award | A | Stock Option (Right to Buy) | 35,500 | 1.44 | 51.1K | 35,500 | D | ↗ |
| 2025-04-01 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 9,581 | 1.44 | 13.7K | 42,280 | D | ↗ |
| 2025-04-01 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 7,841 | 1.44 | 11.3K | 127,609 | D | ↗ |
| 2025-02-18 | Boyle Scott N | Officer | S-Sale | D | Common Stock | 669 | 3.15 | 2.1K | 107,805 | D | ↗ |
| 2025-02-15 | Hirsch Andrew | Director / Officer | F-InKind | D | Common Stock | 9,370 | 3.18 | 29.8K | 423,145 | D | ↗ |
| 2025-02-14 | Siegel Jolie | Officer | A-Award | A | Stock Option (Right to Buy) | 84,700 | 3.18 | 269.3K | 84,700 | D | ↗ |
| 2025-02-14 | Schick Kelly | Officer | A-Award | A | Stock Option (Right to Buy) | 84,700 | 3.18 | 269.3K | 84,700 | D | ↗ |
| 2025-02-14 | REYNO LEONARD | Officer | A-Award | A | Stock Option (Right to Buy) | 130,600 | 3.18 | 415.3K | 130,600 | D | ↗ |
| 2025-02-14 | Mossler Mark | Officer | F-InKind | D | Common Stock | 1,586 | 3.18 | 5.0K | 18,204 | D | ↗ |
| 2025-02-14 | Mahaney Paige | Officer | A-Award | A | Stock Option (Right to Buy) | 42,400 | 3.18 | 134.8K | 42,400 | D | ↗ |
| 2025-02-14 | Hirsch Andrew | Director / Officer | A-Award | A | Common Stock | 223,500 | 0.00 | — | 445,362 | D | ↗ |
| 2025-02-14 | Boyle Scott N | Officer | A-Award | A | Stock Option (Right to Buy) | 84,700 | 3.18 | 269.3K | 84,700 | D | ↗ |
| 2025-02-14 | Adams Kendra | Officer | A-Award | A | Stock Option (Right to Buy) | 130,600 | 3.18 | 415.3K | 130,600 | D | ↗ |
| 2025-02-13 | Siegel Jolie | Officer | F-InKind | D | Common Stock | 2,135 | 3.20 | 6.8K | 54,353 | D | ↗ |
| 2025-02-13 | Schick Kelly | Officer | F-InKind | D | Common Stock | 1,735 | 3.20 | 5.6K | 54,753 | D | ↗ |
| 2025-02-13 | Boyle Scott N | Officer | F-InKind | D | Common Stock | 1,735 | 3.20 | 5.6K | 54,832 | D | ↗ |
| 2025-02-13 | Adams Kendra | Officer | F-InKind | D | Common Stock | 1,863 | 3.20 | 6.0K | 82,576 | D | ↗ |
| 2025-01-02 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 3,757 | 3.66 | 13.8K | 32,699 | D | ↗ |
| 2025-01-02 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 3,074 | 3.66 | 11.3K | 119,768 | D | ↗ |
| 2024-11-19 | Hoerter Steven L. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-07 | Siegel Jolie | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 57,590 | D | ↗ |
| 2024-11-07 | Schick Kelly | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 57,590 | D | ↗ |
| 2024-11-07 | Hirsch Andrew | Director / Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 227,412 | D | ↗ |
| 2024-11-07 | Boyle Scott N | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 57,669 | D | ↗ |
| 2024-11-07 | Adams Kendra | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 85,541 | D | ↗ |
| 2024-10-28 | Mahaney Paige | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-01 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 2,474 | 5.56 | 13.8K | 28,942 | D | ↗ |
| 2024-10-01 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 2,023 | 5.56 | 11.2K | 116,694 | D | ↗ |
| 2024-09-18 | Adams Kendra | Officer | F-InKind | D | Common Stock | 1,837 | 6.38 | 11.7K | 81,791 | D | ↗ |
| 2024-09-16 | Siegel Jolie | Officer | M-Exempt | D | Performance Restricted Stock Units | 2,250 | 0.00 | — | 14,250 | — | ↗ |
| 2024-09-16 | Schick Kelly | Officer | M-Exempt | A | Common Stock | 2,250 | 0.00 | — | 54,501 | — | ↗ |
| 2024-09-16 | Hirsch Andrew | Director / Officer | M-Exempt | D | Performance Restricted Stock Units | 7,500 | 0.00 | — | 47,500 | — | ↗ |
| 2024-09-16 | Fisher Stewart | Officer | M-Exempt | D | Performance Restricted Stock Units | 2,250 | 0.00 | — | 14,250 | — | ↗ |
| 2024-09-16 | Boyle Scott N | Officer | M-Exempt | D | Performance Restricted Stock Units | 2,250 | 0.00 | — | 14,250 | — | ↗ |
| 2024-09-16 | Adams Kendra | Officer | M-Exempt | D | Performance Restricted Stock Units | 2,250 | 0.00 | — | 14,250 | — | ↗ |
| 2024-08-29 | Fawell Stephen | Director | A-Award | A | Stock Option (Right to Buy) | 65,000 | 6.43 | 418.0K | 65,000 | — | ↗ |
| 2024-07-10 | REYNO LEONARD | Officer | F-InKind | D | Common Stock | 6,191 | 5.00 | 31.0K | 91,809 | — | ↗ |
| 2024-07-01 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 2,836 | 4.85 | 13.8K | 26,468 | — | ↗ |
| 2024-07-01 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 2,320 | 4.85 | 11.3K | 114,671 | — | ↗ |
| 2024-06-20 | Salter Malcolm | Director | A-Award | A | Stock Option (Right to Buy) | 32,500 | 4.05 | 131.6K | 32,500 | — | ↗ |
| 2024-06-20 | Koppikar Utpal | Director | A-Award | A | Stock Option (Right to Buy) | 32,500 | 4.05 | 131.6K | 32,500 | — | ↗ |
| 2024-06-20 | Hughes Owen | Director | A-Award | A | Stock Option (Right to Buy) | 32,500 | 4.05 | 131.6K | 32,500 | — | ↗ |
| 2024-06-20 | GROGAN DONNA ROY | Director | A-Award | A | Stock Option (Right to Buy) | 32,500 | 4.05 | 131.6K | 32,500 | — | ↗ |
| 2024-06-20 | DOWNEY BRUCE | Director | A-Award | A | Stock Option (Right to Buy) | 32,500 | 4.05 | 131.6K | 32,500 | — | ↗ |
| 2024-06-20 | Bessen Laura | Director | A-Award | A | Stock Option (Right to Buy) | 32,500 | 4.05 | 131.6K | 32,500 | — | ↗ |
| 2024-06-20 | Anderson Kenneth Carl | Director | A-Award | A | Stock Option (Right to Buy) | 32,500 | 4.05 | 131.6K | 32,500 | — | ↗ |
| 2024-06-07 | Cooper Ronald Harold Wilfred | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-01 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 1,697 | 8.10 | 13.7K | 23,632 | — | ↗ |
| 2024-04-01 | Dubin Glenn | Director | A-Award | A | Common Stock | 1,358 | 8.10 | 11.0K | 22,075 | — | ↗ |
| 2024-04-01 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 1,389 | 8.10 | 11.3K | 112,351 | — | ↗ |
| 2024-03-07 | Siegel Jolie | Officer | D-Return | D | Stock Option (Right to Buy) | 84,850 | 45.54 | 3.86M | 0 | — | ↗ |
| 2024-03-07 | Schick Kelly | Officer | D-Return | D | Stock Option (Right to Buy) | 78,500 | 22.71 | 1.78M | 0 | — | ↗ |
| 2024-03-07 | Fisher Stewart | Officer | D-Return | D | Stock Option (Right to Buy) | 118,000 | 22.71 | 2.68M | 0 | — | ↗ |
| 2024-03-07 | Boyle Scott N | Officer | D-Return | D | Stock Option (Right to Buy) | 115,000 | 33.23 | 3.82M | 0 | — | ↗ |
| 2024-03-07 | Adams Kendra | Officer | D-Return | D | Stock Option (Right to Buy) | 45,000 | 22.71 | 1.02M | 0 | — | ↗ |
| 2024-02-15 | Hirsch Andrew | Director / Officer | F-InKind | D | Common Stock | 6,560 | 7.90 | 51.8K | 210,741 | — | ↗ |
| 2024-02-14 | Siegel Jolie | Officer | A-Award | A | Common Stock | 27,300 | 0.00 | — | 52,251 | — | ↗ |
| 2024-02-14 | Schick Kelly | Officer | A-Award | A | Stock Option (Right to Buy) | 122,800 | 7.31 | 897.7K | 122,800 | — | ↗ |
| 2024-02-14 | REYNO LEONARD | Officer | A-Award | A | Stock Option (Right to Buy) | 165,300 | 7.31 | 1.21M | 165,300 | — | ↗ |
| 2024-02-14 | Mossler Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 27,430 | 7.31 | 200.5K | 27,430 | — | ↗ |
| 2024-02-14 | Hirsch Andrew | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 465,500 | 7.31 | 3.40M | 465,500 | — | ↗ |
| 2024-02-14 | Fisher Stewart | Officer | A-Award | A | Stock Option (Right to Buy) | 122,800 | 7.31 | 897.7K | 122,800 | — | ↗ |
| 2024-02-14 | Boyle Scott N | Officer | A-Award | A | Common Stock | 27,300 | 0.00 | — | 52,330 | — | ↗ |
| 2024-02-14 | Adams Kendra | Officer | A-Award | A | Stock Option (Right to Buy) | 165,300 | 7.31 | 1.21M | 165,300 | — | ↗ |
| 2024-02-13 | Siegel Jolie | Officer | F-InKind | D | Common Stock | 1,735 | 6.53 | 11.3K | 24,951 | — | ↗ |
| 2024-02-13 | Schick Kelly | Officer | F-InKind | D | Common Stock | 1,735 | 6.53 | 11.3K | 24,951 | — | ↗ |
| 2024-02-13 | Fisher Stewart | Officer | F-InKind | D | Common Stock | 2,255 | 6.53 | 14.7K | 101,821 | — | ↗ |
| 2024-02-13 | Boyle Scott N | Officer | F-InKind | D | Common Stock | 1,735 | 6.53 | 11.3K | 25,030 | — | ↗ |
| 2024-02-13 | Adams Kendra | Officer | F-InKind | D | Common Stock | 1,301 | 6.53 | 8.5K | 45,339 | — | ↗ |
| 2024-01-02 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 2,108 | 6.52 | 13.7K | 21,935 | — | ↗ |
| 2024-01-02 | Dubin Glenn | Director | A-Award | A | Common Stock | 1,687 | 6.52 | 11.0K | 20,717 | — | ↗ |
| 2024-01-02 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 1,725 | 6.52 | 11.2K | 110,962 | — | ↗ |
| 2023-11-16 | Hughes Owen | Director | A-Award | A | Stock Option (Right to Buy) | 52,000 | 1.82 | 94.6K | 52,000 | — | ↗ |
| 2023-10-02 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 8,089 | 1.70 | 13.8K | 19,827 | — | ↗ |
| 2023-10-02 | Dubin Glenn | Director | A-Award | A | Common Stock | 6,470 | 1.70 | 11.0K | 19,030 | — | ↗ |
| 2023-10-02 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 6,617 | 1.70 | 11.2K | 109,237 | — | ↗ |
| 2023-09-18 | Siegel Jolie | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 2.15 | 258.0K | 120,000 | — | ↗ |
| 2023-09-18 | Schick Kelly | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 2.15 | 258.0K | 120,000 | — | ↗ |
| 2023-09-18 | Mossler Mark | Officer | — | D | Stock Option (Right to Buy) | 50,210 | 2.83 | 142.1K | 0 | — | ↗ |
| 2023-09-18 | Hirsch Andrew | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 489,600 | 2.15 | 1.05M | 489,600 | — | ↗ |
| 2023-09-18 | Fisher Stewart | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 2.15 | 258.0K | 120,000 | — | ↗ |
| 2023-09-18 | Boyle Scott N | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 2.15 | 258.0K | 120,000 | — | ↗ |
| 2023-09-18 | Adams Kendra | Officer | A-Award | A | Stock Option (Right to Buy) | 111,000 | 2.15 | 238.7K | 111,000 | — | ↗ |
| 2023-08-30 | White Lauren | Officer | M-Exempt | A | Common Stock | 2,250 | 0.00 | — | 33,347 | — | ↗ |
| 2023-08-30 | Siegel Jolie | Officer | M-Exempt | D | Performance Restricted Stock Units | 2,250 | 0.00 | — | 16,500 | — | ↗ |
| 2023-08-30 | Schick Kelly | Officer | M-Exempt | D | Performance Restricted Stock Units | 2,250 | 0.00 | — | 16,500 | — | ↗ |
| 2023-08-30 | Hirsch Andrew | Director / Officer | M-Exempt | D | Performance Restricted Stock Units | 7,500 | 0.00 | — | 55,000 | — | ↗ |
| 2023-08-30 | Fisher Stewart | Officer | M-Exempt | A | Common Stock | 2,250 | 0.00 | — | 104,737 | — | ↗ |
| 2023-08-30 | Boyle Scott N | Officer | M-Exempt | A | Common Stock | 2,250 | 0.00 | — | 27,426 | — | ↗ |
| 2023-07-10 | REYNO LEONARD | Officer | A-Award | A | Common Stock | 61,300 | 0.00 | — | 61,300 | — | ↗ |
| 2023-07-03 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 4,858 | 2.83 | 13.7K | 11,738 | — | ↗ |
| 2023-07-03 | Dubin Glenn | Director | A-Award | A | Common Stock | 3,887 | 2.83 | 11.0K | 12,560 | — | ↗ |
| 2023-07-03 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 3,976 | 2.83 | 11.3K | 102,620 | — | ↗ |
| 2023-06-15 | Salter Malcolm | Director | A-Award | A | Stock Option (Right to Buy) | 26,000 | 3.61 | 93.9K | 26,000 | — | ↗ |
| 2023-06-15 | Koppikar Utpal | Director | A-Award | A | Stock Option (Right to Buy) | 26,000 | 3.61 | 93.9K | 26,000 | — | ↗ |
| 2023-06-15 | GROGAN DONNA ROY | Director | A-Award | A | Stock Option (Right to Buy) | 26,000 | 3.61 | 93.9K | 26,000 | — | ↗ |
| 2023-06-15 | Dubin Glenn | Director | A-Award | A | Stock Option (Right to Buy) | 26,000 | 3.61 | 93.9K | 26,000 | — | ↗ |
| 2023-06-15 | DOWNEY BRUCE | Director | A-Award | A | Stock Option (Right to Buy) | 26,000 | 3.61 | 93.9K | 26,000 | — | ↗ |
| 2023-06-15 | Bessen Laura | Director | A-Award | A | Stock Option (Right to Buy) | 26,000 | 3.61 | 93.9K | 26,000 | — | ↗ |
| 2023-06-15 | Anderson Kenneth Carl | Director | A-Award | A | Stock Option (Right to Buy) | 26,000 | 3.61 | 93.9K | 26,000 | — | ↗ |
| 2023-04-03 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 4,298 | 3.20 | 13.8K | 6,880 | — | ↗ |
| 2023-04-03 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 3,516 | 3.20 | 11.3K | 98,644 | — | ↗ |
| 2023-02-15 | Hirsch Andrew | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 367,200 | 5.77 | 2.12M | 367,200 | — | ↗ |
| 2023-02-13 | White Lauren | Officer | A-Award | A | Common Stock | 26,000 | 0.00 | — | 31,097 | — | ↗ |
| 2023-02-13 | Siegel Jolie | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 25,097 | — | ↗ |
| 2023-02-13 | Schick Kelly | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 25,097 | — | ↗ |
| 2023-02-13 | Fisher Stewart | Officer | A-Award | A | Common Stock | 26,000 | 0.00 | — | 102,487 | — | ↗ |
| 2023-02-13 | Boyle Scott N | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 25,176 | — | ↗ |
| 2023-02-08 | Koppikar Utpal | Director | P-Purchase | A | Common Stock | 5,667 | 5.60 | 31.7K | 5,667 | — | ↗ |
| 2023-01-30 | White Lauren | Officer | M-Exempt | D | Performance Restricted Stock Units | 3,750 | 0.00 | — | 18,750 | — | ↗ |
| 2023-01-30 | Siegel Jolie | Officer | F-InKind | D | Common Stock | 1,301 | 7.78 | 10.1K | 5,097 | — | ↗ |
| 2023-01-30 | Schick Kelly | Officer | F-InKind | D | Common Stock | 1,301 | 7.78 | 10.1K | 5,097 | — | ↗ |
| 2023-01-30 | Hirsch Andrew | Director / Officer | F-InKind | D | Common Stock | 4,319 | 7.78 | 33.6K | 27,006 | — | ↗ |
| 2023-01-30 | Fisher Stewart | Officer | M-Exempt | D | Performance Restricted Stock Units | 3,750 | 0.00 | — | 18,750 | — | ↗ |
| 2023-01-30 | Crystal Adam | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 21,398 | — | ↗ |
| 2023-01-30 | Boyle Scott N | Officer | F-InKind | D | Common Stock | 1,222 | 7.78 | 9.5K | 5,176 | — | ↗ |
| 2023-01-06 | Anderson Kenneth Carl | Director | M-Exempt | A | Common Stock | 444 | 4.98 | 2.2K | 95,128 | — | ↗ |
| 2023-01-03 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 1,763 | 6.38 | 11.2K | 2,582 | — | ↗ |
| 2023-01-03 | Dubin Glenn | Director | A-Award | A | Common Stock | 1,725 | 6.38 | 11.0K | 5,235 | — | ↗ |
| 2023-01-03 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 1,568 | 6.38 | 10.0K | 94,416 | — | ↗ |
| 2022-10-03 | GROGAN DONNA ROY | Director | A-Award | A | Common Stock | 819 | 8.69 | 7.1K | 819 | — | ↗ |
| 2022-10-03 | Dubin Glenn | Director | A-Award | A | Common Stock | 1,265 | 8.69 | 11.0K | 3,510 | — | ↗ |
| 2022-10-03 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 1,150 | 8.69 | 10.0K | 92,848 | — | ↗ |
| 2022-07-29 | GROGAN DONNA ROY | Director | A-Award | A | Stock Option (Right to Buy) | 41,200 | 0.00 | — | 41,200 | — | ↗ |
| 2022-07-29 | Bessen Laura | Director | A-Award | A | Stock Option (Right to Buy) | 41,200 | 0.00 | — | 41,200 | — | ↗ |
| 2022-07-15 | Anderson Kenneth Carl | Director | M-Exempt | D | Stock Option (Right to Buy) | 889 | 4.98 | 4.4K | 1,779 | — | ↗ |
| 2022-07-01 | Dubin Glenn | Director | A-Award | A | Common Stock | 1,372 | 8.03 | 11.0K | 2,245 | — | ↗ |
| 2022-07-01 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 1,246 | 8.03 | 10.0K | 89,562 | — | ↗ |
| 2022-06-22 | Salter Malcolm | Director | A-Award | A | Stock Option (Right to Buy) | 23,500 | 0.00 | — | 23,500 | — | ↗ |
| 2022-06-22 | Dubin Glenn | Director | A-Award | A | Stock Option (Right to Buy) | 23,500 | 0.00 | — | 23,500 | — | ↗ |
| 2022-06-22 | DOWNEY BRUCE | Director | A-Award | A | Stock Option (Right to Buy) | 23,500 | 0.00 | — | 23,500 | — | ↗ |
| 2022-06-22 | COHEN MARC A | Director | A-Award | A | Stock Option (Right to Buy) | 23,500 | 0.00 | — | 23,500 | — | ↗ |
| 2022-06-22 | Anderson Kenneth Carl | Director | A-Award | A | Stock Option (Right to Buy) | 23,500 | 6.06 | 142.4K | 23,500 | — | ↗ |
| 2022-05-26 | White Lauren | Officer | F-InKind | D | Common Stock | 1,102 | 7.01 | 7.7K | 2,648 | — | ↗ |
| 2022-05-26 | Siegel Jolie | Officer | F-InKind | D | Common Stock | 1,102 | 7.01 | 7.7K | 2,648 | — | ↗ |
| 2022-05-26 | Schick Kelly | Officer | F-InKind | D | Common Stock | 1,102 | 7.01 | 7.7K | 2,648 | — | ↗ |
| 2022-05-26 | Hirsch Andrew | Director / Officer | F-InKind | D | Common Stock | 3,675 | 7.01 | 25.8K | 18,825 | — | ↗ |
| 2022-05-26 | Fisher Stewart | Officer | F-InKind | D | Common Stock | 1,102 | 7.01 | 7.7K | 74,038 | — | ↗ |
| 2022-05-26 | Crystal Adam | Officer | F-InKind | D | Common Stock | 1,102 | 7.01 | 7.7K | 17,648 | — | ↗ |
| 2022-05-26 | Boyle Scott N | Officer | F-InKind | D | Common Stock | 1,102 | 7.01 | 7.7K | 2,648 | — | ↗ |
| 2022-05-25 | White Lauren | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 3,750 | — | ↗ |
| 2022-05-25 | Siegel Jolie | Officer | M-Exempt | D | Performance Restricted Stock Units | 3,750 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-25 | Schick Kelly | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 3,750 | — | ↗ |
| 2022-05-25 | Hirsch Andrew | Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-25 | Fisher Stewart | Officer | M-Exempt | D | Performance Restricted Stock Units | 3,750 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-25 | Crystal Adam | Officer | M-Exempt | D | Performance Restricted Stock Units | 3,750 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-25 | Boyle Scott N | Officer | M-Exempt | D | Performance Restricted Stock Units | 3,750 | 0.00 | — | 22,500 | — | ↗ |
| 2022-04-12 | Hirsch Andrew | Officer | P-Purchase | A | Common Stock | 10,000 | 8.40 | 84.0K | 10,000 | — | ↗ |
| 2022-04-12 | Fisher Stewart | Officer | M-Exempt | A | Common Stock | 2,156 | 3.71 | 8.0K | 45,462 | — | ↗ |
| 2022-04-04 | Dubin Glenn | Director | A-Award | A | Common Stock | 379 | 26.46 | 10.0K | 873 | — | ↗ |
| 2022-04-04 | COHEN ALAIN J | Director | A-Award | A | Common Stock | 388 | 26.46 | 10.3K | 928 | — | ↗ |
| 2022-04-04 | Anderson Kenneth Carl | Director | A-Award | A | Common Stock | 341 | 26.46 | 9.0K | 88,316 | — | ↗ |
| 2022-03-16 | Schick Kelly | Officer | — | D | Stock Option (Right to Buy) | 92,000 | 37.46 | 3.45M | 0 | — | ↗ |
| 2022-03-16 | Koppikar Utpal | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-16 | Boyle Scott N | Officer | — | D | Stock Option (Right to Buy) | 115,000 | 33.23 | 3.82M | 0 | — | ↗ |
| 2022-02-23 | Hirsch Andrew | Director / Officer | A-Award | A | Performance Restricted Stock Units | 87,500 | 0.00 | — | 87,500 | — | ↗ |
| 2022-02-14 | White Lauren | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 22.71 | 2.27M | 100,000 | — | ↗ |
| 2022-02-14 | Siegel Jolie | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 22.71 | 2.04M | 90,000 | — | ↗ |
| 2022-02-14 | Fisher Stewart | Officer | A-Award | A | Stock Option (Right to Buy) | 118,000 | 22.71 | 2.68M | 118,000 | — | ↗ |
| 2022-02-14 | Crystal Adam | Officer | A-Award | A | Stock Option (Right to Buy) | 118,000 | 22.71 | 2.68M | 118,000 | — | ↗ |
| 2022-01-26 | Anderson Kenneth Carl | Director | M-Exempt | D | Stock Option (Right to Buy) | 1,334 | 4.98 | 6.6K | 2,668 | — | ↗ |
| 2022-01-04 | Salter Malcolm | Director | A-Award | A | Common Stock | 428 | 31.58 | 13.5K | 11,380 | — | ↗ |
| 2022-01-04 | Dubin Glenn | Director | A-Award | A | Common Stock | 199 | 31.58 | 6.3K | 494 | — | ↗ |
| 2022-01-04 | Crystal Adam | Officer | S-Sale | D | Common Stock | 1,054 | 32.66 | 34.4K | 15,000 | — | ↗ |
| 2022-01-04 | COHEN MARC A | Director | A-Award | A | Common Stock | 657 | 31.58 | 20.7K | 1,118 | — | ↗ |
| 2022-01-04 | COHEN ALAIN J | Director | A-Award | A | Common Stock | 318 | 31.58 | 10.0K | 540 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-9.5K
Shares Outstanding
82.83M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Andrew J. Hirsch President & Chief Executive Officer | 694.9K | 100.0K | 710.7K | 848.0K | 573.3K | 14.0K | 2.94M | 53.00% | ↗ |
| 2 | 2025 | Leonard Reyno, M.D. Chief Medical Officer | 597.7K | 100.0K | 277.0K | 330.3K | 322.8K | 14.0K | 1.64M | 36.99% | ↗ |
| 3 | 2025 | Kendra R. Adams Chief Financial Officer | 506.8K | 75.0K | 277.0K | 330.3K | 273.7K | 14.0K | 1.48M | 41.12% | ↗ |
| 4 | 2024 | Andrew J. Hirsch President & Chief Executive Officer | 665.0K | — | 755.9K | 2.80M | 402.3K | 13.8K | 4.63M | 76.66% | ↗ |
| 5 | 2024 | Leonard Reyno, M.D. Chief Medical Officer | 572.0K | — | 268.3K | 992.9K | 251.7K | 13.8K | 2.10M | 60.09% | ↗ |
| 6 | 2024 | Kendra R. Adams Chief Financial Officer | 485.0K | — | 268.3K | 1.00M | 213.4K | 12.8K | 1.98M | 64.12% | ↗ |
| 7 | 2023 | Andrew J. Hirsch President & Chief Executive Officer | 639.0K | — | 470.8K | 2.33M | 333.9K | 13.2K | 3.79M | 73.98% | ↗ |
| 8 | 2023 | Leonard Reyno, M.D. Chief Medical Officer | 262.7K | 268.4K | 214.6K | 709.6K | 209.0K | 10.5K | 1.67M | 55.18% | ↗ |
| 9 | 2023 | Stewart Fisher, Ph.D. Chief Scientific Officer | 479.2K | — | 147.4K | 711.9K | 182.0K | 13.3K | 1.53M | 56.02% | ↗ |
| 10 | 2023 | Kendra R. Adams Chief Financial Officer | 404.6K | — | 138.8K | 489.0K | 171.0K | 7.3K | 1.21M | 51.86% | ↗ |
| 11 | 2022 | Scott N. Boyle, Ph.D. Chief Business Officer | 398.7K | 100.0K | 558.7K | 2.68M | 159.1K | 14.9K | 3.91M | 82.81% | ↗ |
| 12 | 2022 | Stewart Fisher, Ph.D. Chief Scientific Officer | 460.8K | — | 558.7K | 1.89M | 184.3K | 12.2K | 3.10M | 78.83% | ↗ |
| 13 | 2022 | Andrew J. Hirsch President & Chief Executive Officer | 614.4K | — | 1.62M | — | 337.9K | 18.7K | 2.60M | 62.59% | ↗ |
| 14 | 2021 | Lauren A. White Chief Financial Officer | 220.3K | 60.0K | — | 3.70M | 102.8K | 6.0K | 4.09M | 90.48% | ↗ |
| 15 | 2021 | Stewart Fisher, Ph.D. Chief Scientific Officer | 434.7K | 54.0K | — | 3.09M | 200.0K | 6.0K | 3.79M | 81.66% | ↗ |
| 16 | 2021 | Adam S. Crystal, M.D., Ph.D. Chief Medical Officer | 434.7K | 61.0K | — | 2.86M | 200.0K | 6.0K | 3.56M | 80.31% | ↗ |
| 17 | 2021 | Jolie M. Siegel Chief Legal Officer & Secretary | 414.0K | — | — | 2.77M | 190.4K | 6.0K | 3.38M | 81.92% | ↗ |
| 18 | 2021 | Andrew J. Hirsch President & Chief Executive Officer | 579.6K | — | — | — | 366.6K | 6.0K | 952.2K | 0.00% | ↗ |
| 19 | 2021 | William T. McKee Former Chief Financial Officer | — | — | — | — | — | 348.4K | 348.4K | 0.00% | ↗ |
| 20 | 2020 | Andrew J. Hirsch President & Chief Executive Officer | 167.9K | — | — | 20.66M | 98.8K | 5.6K | 20.93M | 98.70% | ↗ |
| 21 | 2020 | Marc A. Cohen Interim Chief Executive Officer | — | — | — | 9.06M | — | 69.5K | 9.13M | 99.24% | ↗ |
| 22 | 2020 | William T. McKee Former Chief Financial Officer | — | — | — | 1.03M | — | 1.07M | 2.10M | 48.83% | ↗ |
| 23 | 2020 | William T. McKee Chief Financial Officer | — | — | — | 1.03M | — | 1.07M | 2.10M | 48.83% | ↗ |
| 24 | 2020 | Adam S. Crystal, M.D., Ph.D. Chief Medical Officer | 409.8K | 61.0K | — | 941.8K | 184.8K | 6.0K | 1.60M | 58.74% | ↗ |
| 25 | 2020 | Stewart Fisher, Ph.D. Chief Scientific Officer | 379.7K | 54.0K | — | 963.5K | 186.5K | 6.0K | 1.59M | 60.61% | ↗ |
| 26 | 2020 | Andrew Phillips, Ph.D. Former President & Chief Executive Officer | 94.5K | — | — | — | — | 523.8K | 618.3K | 0.00% | ↗ |
| 27 | 2019 | Andrew Phillips, Ph.D. Former President & Chief Executive Officer | 520.0K | — | — | 3.38M | 260.0K | 36.4K | 4.19M | 80.53% | ↗ |
| 28 | 2019 | Adam S. Crystal, M.D., Ph.D. Chief Medical Officer | 344.3K | 100.0K | — | 1.12M | 120.5K | 6.4K | 1.69M | 66.21% | ↗ |
| 29 | 2019 | Stewart Fisher, Ph.D. Chief Scientific Officer | 340.3K | — | — | — | 119.1K | 6.3K | 465.8K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrew J. Hirsch | Chief Executive Officer, President & Director | 1M | male |
| Leonard J. Reyno | Chief Medical Officer | 1M | — |
| Kendra Adams | Chief Financial Officer and Head of Corporate Affairs & Treasurer | 869.5K | female |
| Paige Mahaney | Chief Scientific Officer | 657.3K | female |
| Kenneth C. Anderson | Co-Founder, Independent Director & Member of Scientific Advisory Board | 45.8K | — |
| Courtney Solberg | Senior Manager of Investor Relations | — | female |
| Isabel Chiu | Senior Vice President of Strategic Alliances & Business Development | — | — |
| Mark Mossler | Chief Accounting Officer | — | male |
| Nathanael S. Gray | Co-Founder & Member of Scientific Advisory Board | — | — |
| Christopher Nasveschuk | Senior Vice President of Chemistry | — | — |
| Kelly Schick | Chief People Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CCCC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
